{"filing":{"accession_number":"0001493152-26-047841","cik":"0001716166","ticker":"VVOS","company_name":"Vivos Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-21","report_date":"2026-10-20","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226047841/form8-k.htm"},"events":[{"id":36578,"run_id":33725,"accession_number":"0001493152-26-047841","anchor_item_number":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"The filing discloses that Vivos received a deficiency notice from Nasdaq in April 2026 for failing to meet continued listing requirements (minimum $2.5M stockholders' equity, $35M market value, or $500K net income). On October 20, 2026, Nasdaq confirmed compliance with the stockholders' equity requirement following the SOD acquisition, but explicitly warned that \"if the Company fails to evidence compliance upon the filing of its next periodic report, the Company may be subject to delisting.\" This is a material delisting risk disclosure under Item 8.01, as the company remains conditionally compliant and faces imminent delisting if it fails to maintain the equity threshold.","company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","filing_date":"2026-10-21","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":41037,"accession_number":"0001493152-26-047841","item_number":null,"item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Vivos received a deficiency notice from Nasdaq in April 2026 for failing to meet continued listing requirements (minimum $2.5M stockholders' equity, $35M market value, or $500K net income). On October 20, 2026, Nasdaq confirmed compliance with the stockholders' equity requirement following the SOD acquisition, but explicitly warned that \"if the Company fails to evidence compliance upon the filing of its next periodic report, the Company may be subject to delisting.\" This is a material delisting risk disclosure under Item 8.01, as the company remains conditionally compliant and faces imminent delisting if it fails to maintain the equity threshold.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T11:01:46.895102+00:00","company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","filing_date":"2026-10-21"}]}